High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin
High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin
复制标题
DOI：
10.1007/s00280-014-2477-x
复制
发表时间：
2014-07-01
影响因子：
3
通讯作者：
de la Garza-Salazar, Jaime
中科院分区：
文献类型：
--
作者：
Arrieta, Oscar;Medina, Luis-Alberto;de la Garza-Salazar, Jaime
目前还没有可用于晚期胸膜间皮瘤的生物标志物来确定哪些患者可以从特定的化疗方案中获益。基于先前发表的一项II期研究结果，我们将（99m） technology -labelled liposomal doxorubicin （Tc-99m-LD）摄取值（75% cut- cut）与多柔比星和顺铂联合治疗的患者的缓解率、无进展生存期和总生存期联系起来。Tc-99m-LD摄取增加的肿瘤患者的应答率、无进展生存期和总生存期均优于摄取较低的患者（73.3% vs 15%） （p < 0.001）；分别为6.9 vs 3.2个月（p = 0.033）和23 vs 6.6个月（p = 0.001）。肿瘤组织中Tc-99m-DL的摄取可以确定一组将从这种化疗方案中受益的患者。
There are currently no available biomarkers for advanced pleural mesothelioma that determine which patients could benefit from a specific chemotherapy regimen.Based on the results of a previously published phase II study, we associated the (99m)Technetium-labelled liposomal doxorubicin (Tc-99m-LD) uptake value (75 % cut-off) with the response rate, progression-free survival and overall survival of patients treated with a combination of liposomal doxorubicin and cisplatin.Patients with tumours exhibiting increased Tc-99m-LD uptake showed better response rates, progression-free survival and overall survival than those exhibiting lower uptake 73.3 versus 15 % (p < 0.001); 6.9 versus 3.2 months (p = 0.033) and 23 versus 6.6 months (p = 0.001), respectively.Tc-99m-DL uptake in tumour tissue could define a set of patients who would benefit from this chemotherapy regimen.